Atopic dermatitis (AD) is a common chronic inflammatory skin disease that predominantly affects children. However, it can persist in adulthood and/or start at older ages. Due to its chronic nature and frequently occurring relapses, AD has a substantial effect on patients' quality of life, often requiring long-term systemic treatment, especially in adult patients, who are more frequently refractory to adequate topical treatment with mid-to high-potent corticosteroids and/or calcineurin inhibitors. Therefore, treatment with systemic therapies is often needed to take control of the disease, prevent exacerbations and improve quality of life. However, data regarding systemic treatment effectiveness and long-term safety in adult patients with AD are insufficient. Indeed, standardized international guidelines are lacking, and the treatment approach widely differs among diverse countries. This review focuses on the use of systemic treatments in adult AD patients analyzing published literature.
INTRODUCTION
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that predominantly affects children. Indeed, it shows a prevalence up to 20% in children [1, 2] . However, although in 60% of patients AD manifests in childhood, it can start at any age [3] . Prevalence data on adult AD are variable, reporting percentages ranging from 1% to 10% [1, 2, 4] . However, recent studies suggest that the prevalence of both persistent disease (AD developed in childhood with a chronic relapsing course until adulthood) and adult-onset disease (AD directly started later in life, i.e., after 18 years of age) is increased over time along with an increase in the incidence of childhood AD [3] [4] [5] [6] .
Therefore, it is conceivable that adulthood AD cases tend to be more frequent than in the past when it was commonly believed that the disease usually disappeared in late childhood in up to 60% of cases [7] . The course of AD can be continuous for long periods or showing a relapsing-remitting nature with repeated flare-ups. Since AD in adults, especially for persistent disease, is frequently refractory to adequate topical treatment with mid-to high-potent corticosteroids and/or calcineurin inhibitors, a long-term treatment with oral immunosuppressive therapy is often required to control the burden of the disease, prevent flare-ups and achieve better patient quality of life outcomes [4, 8, 9] . However, systemic treatment of adult AD has not been well characterized yet, and data for the long-term safety and comparative effectiveness of systemic immunosuppressive therapies are insufficient. Therefore, large variations exist in adult AD systemic treatment approaches worldwide also because of the lack of international standardized guidelines. The current review focuses on the use of systemic therapies in adult AD patients, analyzing existing literature.
METHODS
We searched for English-language literature regarding systemic therapies in adult AD patients in the following databases through 10 October 2016: PubMed, Embase, The Cochrane Library, Google Scholar, EBSCO and Scopus. The following key words were used: ''adult atopic dermatitis,'' ''adult atopic eczema,'' ''systemic treatment,'' ''systemic therapy,'' ''atopic dermatitis,'' ''adulthood,'' ''adult,'' ''phototherapy,'' ''corticosteroids,'' ''cyclosporine,'' ''methotrexate,'' ''azathioprine, '' ''mycophenolic acid,'' ''mycophenolate mofetil,'' ''alitretinoin,'' ''apremilast,'' ''rituximab,'' ''biologics,'' ''ustekinumab,'' ''omalizumab'' and ''dupilumab.''
All the published articles (case report, case series, prospective and retrospective studies, clinical trials, reviews, guidelines, and consensus) were reviewed to provide a complete overview of systemic therapy for adult AD patients, also
giving detailed data about new targeted therapies, which represent an exciting perspective for the management of severe forms of adult AD. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
Adult AD Management: Systemic Therapy
When topical treatments fail, systemic therapies are required. Adult AD management is challenging and should integrate a therapeutic education program. Systemic treatments are recommended in severe, chronic and resistant forms of AD, after careful evaluation in a reference center [4, 5] . In 2008, a survey analyzing a representative sample of 11,555 patients (60% adults) with AD enrolled from a population-based administrative health care database confirmed insufficient care and medical treatment of AD in routine practice [10] . Moreover, the literature is constantly enriched by studies that show adult AD as a possible systemic disease, being associated with metabolic and cardiovascular comorbidities further complicating treatment of these patients with systemic drugs (e.g., alitretinoin should be carefully used for patients with dyslipidemia, cyclosporine should be carefully used in patients with hypertension, etc.) [11] [12] [13] [14] [15] . Systemic antiinflammatory therapy is appropriate for severe AD patients; about 10% of adult patients receive systemic antiinflammatory therapy at some point during the course of their disease, while in children it is rarely employed [16] . Long-term treatment with oral immunosuppressive therapy is usually introduced when topical treatment with midto high-potent corticosteroids and/or calcineurin inhibitors is not successful. Cyclosporine is the most widely used agent, administered with excellent effects as short-term treatment as well as maintenance therapy in both adults and children [17] . In addition, other immunosuppressive agents such as azathioprine, mycophenolate mofetil and methotrexate may be helpful for the treatment of relapsing and severe forms of AD [17, 18] . However, it is usually important to combine these immunosuppressive treatments with topical therapy to better control the burden of the disease [19] . Ultraviolet (UV) therapy is another alternative treatment to consider when topical treatments fail. Narrow-band UVB radiation and medium-dose UVA1 have been reported to be effective for AD, in particular for AD patients resistant to topical corticosteroids or patients experiencing side effects due to systemic treatments [20] . However, data regarding systemic treatment effectiveness and long-term safety in adult AD are limited, and further studies are needed also to standardize and regulate their use among different countries [1, 4, [21] [22] [23] [24] .
Phototherapy
Artificial UV radiation is frequently used as a second-line treatment for moderate-to-severe AD in adults [24, 25] . By reducing the number of epidermal nerve fibers and the expression of axon guidance molecules, it is also considered a good therapeutic approach for AD-associated itch, relieving patients from this oppressive symptom [26, 27] . Moreover, UV irradiation is also able to modulate the immune response of AD patients via upregulation of FoxP3-positive regulatory T cells, whose number is directly correlated with the degree of AD severity score improvements [28] . Different artificial light sources are available against AD: broadband UVB (290-320 nm), narrow-band (NB) UVB (311-313 nm), excimer laser (308 nm), UVA-1 (340-400 nm), psoralens and UVA (PUVA), and combined UVA/UVB (280-400 nm). Their efficacy is linked to the ability to inhibit DNA synthesis and keratinocyte proliferation, suppression of the antigen-presenting function of the Langerhans' cells, T lymphocyte apoptosis induction and antiinflammatory mediator production [29] . A complete review of the published literature on this topic, including a total of 428 studies regarding the efficacy and safety of phototherapy [30] , as well as an up-to-date review on 19 randomized controlled trials (including 905 participants) [31] confirmed that medium-dose UVA1 and NB-UVB phototherapies are the most effective and safe modalities for adult AD treatment as also observed in various randomized controlled trials and other studies [24, [32] [33] [34] [35] [36] [37] . As a rule, phototherapy is not indicated in the acute stage of AD (except UVA1, which is also effective in managing AD flares) [38] [39] [40] , but is more apt to treat chronic, pruritic, lichenified forms [24, 35] , and should not be prescribed in those patients who experience a worsening of their dermatosis during sun exposure as in the case of other common chronic inflammatory diseases such as psoriasis [41] . In general, NB-UVB has been indicated for chronic-moderate forms of AD and is currently preferred to broadband UV because it is less erythemogenic; a recent study reported that the combination with UVA did not show any further benefits [42] . On the other hand, medium-dose UVA1 appears to be similar to NB-UVB in terms of efficacy, as shown in different studies [43, 44] . In summary, phototherapy can be used as both short-and long-term treatment with variable scheduling including a minimum of thrice weekly access [45] . Nevertheless, it is considered a safe and well-tolerated therapeutic approach, it is limited by the inconvenience and possible adverse events, including limited access to in-office treatment, difficulty adhering to a thrice-weekly schedule, erythema, photodamage, actinic keratosis, blistering and herpes virus reactivation. On the other hand, long-term side effects such as premature photoaging and carcinogenesis have not been excluded [35, 37] . Safe use of NB-UVB and medium-dose UVA1 has been well documented, and it was cited as the most commonly used wave length and modality of light-based therapy for AD [30, 31, 34, 45] . UV can also be combined with a prior (oral or topical) administration of photosensitizing drugs such as psoralens (photochemotherapy). Psoralens are used with UVA (PUVA). Generally, photochemotherapy is not considered the first phototherapy modality of treatment, especially for oral PUVA, which may present several side effects including nausea, headache, fatigue, burning skin, itching and irregular skin pigmentation as well as a higher risk of skin cancer, so that the risk/benefit ratio of this treatment must be carefully weighed [24, 31, 45] . Moreover, it should be also stated that most patients favor NB-UVB or UVA1 [18] . An overview of systemic treatments for adult AD is displayed in Table 1 .
Oral Corticosteroids
Systemic corticosteroids are rapidly effective as suggested that treatment with oral prednisolone (0.5-0.8 mg/kg daily) for 2 weeks was not able to induce a stable remission of AD, even when associated with topical steroids [53] . Moreover, even though the authors also demonstrated equal efficacy of therapy with systemic glucocorticosteroids as cyclosporine analyzing 21 vs. 17 AD patients, respectively, they concluded that despite its frequent use in daily practice, prednisolone is not recommended to induce stable remission of eczema [53] . [24] .
Azathioprine
Azathioprine is a purine synthesis inhibitor that reduces leukocyte proliferation. It is used off label for treatment of severe AD in adults, in particular in the UK and USA [50] . Two randomized, double-blind, placebo-controlled studies (enrolling 37 and 63 subjects, respectively) [67, 68] , and one single-blinded randomized controlled trial comparing azathioprine with methotrexate (n = 42) [69] showed that azathioprine was superior to placebo, with a significant clinical improvement in disease severity (26% and 37% on clinical outcome scales after 3 months), and had a clinical efficacy equal to that of methotrexate with an expected average reduction in disease activity of about 40%. Since then, several uncontrolled studies conducted in both adults and children have demonstrated similar results [70, 71] . In particular, azathioprine efficacy was tested in a retrospective uncontrolled study involving 48 children and adolescents aged 6-16 years diagnosed with severe AD [72] . All patients started with a dose of 2 mg/kg twice a day, and the dose was increased to 3 mg/kg twice a day in 14 patients because of insufficient clinical response. The mean time to achieve clinical response was 4 weeks. None of the patients showed myelotoxic symptoms. After 3 months of therapy, 28 patients (58.3%) showed excellent results and 13 patients (27.1%) showed good improvement, whereas only 7 patients (14.6%) showed little or no improvement. In 2009, another retrospective uncontrolled study including 17 patients (mean age of 16.1 ± 3.9 years) with recalcitrant AD showed significant improvement of SCORAD after 3 months and 6 months of treatment with azathioprine as well as significant reduction in total serum IgE levels [73] . Azathioprine has an intriguing metabolism with several immunosuppressant metabolites, governed by thiopurine methyltransferase activity (TPMT), so that the azathioprine dosage should be determined based on the TPMT genotype or activity levels to limit the possible appearance of myelotoxicity. A randomized control trial
showed that adult patients with AD in whom the azathioprine dose was adapted to TPMT activity had similar disease improvement compared with patients with normal TPMT activity receiving 2.5 mg/kg azathioprine [68] . [89] . Moreover, since alitretinoin is teratogenic, all women of childbearing age must adhere to a strict birth control program.
Overall studies supporting alitretinoin efficacy in adult AD patients are limited. Its use may be suggested in atopic hand eczema in adult patients unresponsive to topical steroid and tacrolimus [24] .
Biologics
The development of biological therapies has rapidly progressed during the last few years. Although none of these biologic drugs have been approved for the treatment of adult AD so far, dupilumab has received breakthrough therapy designation and has been accepted for priority review from the US Food and Drug Administration (FDA) for the treatment of adult patients with inadequately controlled moderate-to-severe AD, and different clinical trials are now being conducted to determine the efficacy, dosing and long-term safety of these promising therapies [92] . Biological drugs, especially dupilumab, appears to be a promising treatment for adult AD patients, because they offer more convenient dose regimens and less frequent laboratory monitoring than other systemic therapies as well as fewer side effects (see Table 1 for details).
Future studies are needed to overcome unmet needs and to reach high and better standards of care for AD patients. In this context, dupilumab represents a promising drug that may have a positive and deep impact on the adult AD world.
Rituximab
T cells play a key role in the pathogenetic pathway of AD, but B cells might also participate in its development. Data about rituximab, a monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells, used for adult AD patient treatment, are limited. To date, evidence for the efficacy of rituximab in treating adult patients with severe AD is exclusively based on case reports and series [93, 94] . Rituximab, acting by decreasing B cells, was reported to be effective in reducing skin inflammation in six patients with AD, treated with two 1000-mg intravenous infusions, 2 weeks apart [93] . All patients showed an improvement of their skin symptoms within 4-8 weeks [93] . Moreover, another study regarding two AD patients who received a lower dose of rituximab (two doses of 500 mg each, 2 weeks apart), showed only limited effects [94] . One patient improved, with the SCORAD score reducing from 99 to 58 at week 10, but the other experienced an AD worsening with the SCORAD score increasing from 63 to 74 at week 10. A further study on four patients with severe AD was reported [95] ; patients were given a cycled therapy of omalizumab and [99, 100] . Moreover, recently, Weiss et al. related that ustekinumab was able to achieve a 50% reduction in the EASI Index score by week 16 in three adult AD patients together with a decrease in the degree of epidermal hyperplasia/proliferation, the number of infiltrating dermal T cells, dendritic cells and mast cells as well as in T-helper 2-/22-associated molecules [101] . In all these studies, ustekinumab (45 mg) was administered following the established protocol for psoriasis, despite patient weight. On the other hand, a recent phase II, double-blind, placebo-controlled study with 33 patients with moderate-to-severe AD randomly assigned to either ustekinumab (n = 16) or placebo (n = 17), with subsequent crossover at 16 weeks, and the last dose at 32 weeks, showed that the ustekinumab group achieved higher SCORAD50 responses at 12, 16 and 20 weeks compared to placebo, however without approaching statistical significance [102] . In this trial, dosing of ustekinumab followed the recommendations for psoriasis, namely 45 and 90 mg per injection for patients weighing B100 or [100 kg, respectively, and the authors also observed that ustekinumab could determine a significant modulation of Th1, Th17 and Th22 and Th2-related AD genes after 4 weeks of treatment (i.e., MMP12, IL-22, IL-13, IFN-c, elafin/PI3, CXCL1, CCL17) [102] . In addition, other authors reported inadequate response to ustekinumab treatment in two adult AD patients even if with the addition of aggressive topical corticosteroid therapy, whereas Lis-Święty et al. observed an exacerbation of AD under ustekinumab therapy in a psoriatic patient with a childhood history of atopy [103, 104] . In summary, data regarding ustekinumab efficacy in adult AD are controversial and scant, with the only existing double-blind placebo-controlled study lacking evidence of statistically significant efficacy.
Further studies are needed to investigate its role in adult AD treatment.
Omalizumab
Omalizumab is a recombinant, humanized monoclonal antibody against the high-affinity Fc receptor of human IgE (FceRI), which is administered subcutaneously. The US FDA has approved this drug for severe allergic asthma and chronic spontaneous urticaria treatment [105] . Since AD may share a common pathologic mechanism with asthma (high IgE levels in blood), omalizumab has been also used to treat patients with severe forms of AD associated with high IgE blood levels [106] [107] [108] , reporting a significant efficacy in improving AD-related quality of life scores [109] . Omalizumab induces lymphocyte polarization toward a type 2 immune response and quenches eosinophil-mediated inflammation [110] . Currently available data on AD treatment with omalizumab are controversial [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] . however, no placebo group was included in the study [123] . Moreover, a prospective analysis including 21 patients (14-64 years old) with moderate-to-severe persistent allergic asthma and AD showed a statistically significant clinical improvement of AD in all patients [124] . filaggrin mutations may benefit from this treatment [127] . Omalizumab ineffectiveness in adult AD patients is also supported by other studies [128, 129] [130, [134] [135] [136] [137] [138] [139] [140] . The clinical benefit was supported by the improvement in the serum levels of Th2-associated biomarkers, such as thymus and activation-regulated chemokine (TARC), total IgE and eosinophil counts [136] and by the improvement of the AD molecular signature tested with transcriptomic analyses of pre-and post-treatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg dupilumab [137] .
The best data supporting its efficacy and safety came from two randomized, [130] . In all clinical studies to date, dupilumab has shown a favorable safety profile with no dose-limiting toxicity and few adverse effects [141] [142] [143] . These include nasopharyngitis, upper respiratory tract infections, headache, injection-site reaction and back pain [130, [141] [142] [143] . Due to these promising results, dupilumab has the potential to become the first biological systemic therapy for AD treatment in adult patients unresponsive to topical corticosteroids or topical calcineurin inhibitors [143] . Recently, it received the US FDA breakthrough therapy designation for AD, with ongoing trials in both adult and pediatric populations [143] . For all these reasons, dupilumab will probably completely change the treatment opportunities for severe adult AD in the following years, presenting the most efficacious and safe systemic treatments for these patients. 
Small Molecules

Apremilast
Apremilast is a novel oral agent that modulates multiple antiinflammatory pathways targeting phosphodiesterase type IV (PDE4) inhibition. It has been studied for the treatment of asthma, chronic obstructive pulmonary disease, psoriasis and psoriatic arthritis (PsA) [145] . In 2014, apremilast was approved by the US FDA for the treatment of active PsA in adults and of moderate-to-severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy [146] . Literature data investigating the role of apremilast in treating recalcitrant forms of adult AD are limited. In
2014, an open-label pilot study involving 16 adult patients (age C18 years) with moderate-to-severe AD who were treated with apremilast was performed [147] . Particularly, six patients received 20 mg twice daily for 3 months (Cohort1), while the other ten patients received apremilast 30 mg twice daily for a total of 6 months (Cohort2). This treatment resulted in a significant reduction of the EASI score with an average of 19% in Cohort1 and 39% in Cohort 2 at 3 months [147] . Nausea was the most common side effect followed by diarrhea and headache; an episode of herpes zoster during the treatment period was reported [147] . Previously, a phase 2, open-label, investigator-initiated study reported the safety and efficacy of apremilast (20 mg twice daily for 12 weeks) in ten patients with either AD and/or allergic contact dermatitis. Ten percent of patients achieved EASI-75, whereas another 10% achieved EASI-50; 20% had an improvement by two or more points of IGA [148] . To date, limited data are available for apremilast use in AD patients.
Even though apremilast has been shown to be an interesting and promising drug, especially due to its safety profile, further studies are needed to clearly assess its efficacy in the treatment of moderate-to-severe recalcitrant adult AD. 64. Ohtsuka T. Different effect of oral cyclosporine therapy and oral antihistamine therapy on serum high-sensitivity C-reactive protein level and thymus and activation-regulated chemokine level in atopic dermatitis in older children and adulthood. Int J Dermatol. 2015;54:648-55.
CONCLUSION
